Deltec Asset Management LLC Makes New $514,000 Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Deltec Asset Management LLC bought a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) in the 4th quarter, HoldingsChannel reports. The fund bought 194,124 shares of the company’s stock, valued at approximately $514,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. GSA Capital Partners LLP raised its position in Aerovate Therapeutics by 226.8% during the third quarter. GSA Capital Partners LLP now owns 413,795 shares of the company’s stock valued at $865,000 after buying an additional 287,163 shares during the period. Barclays PLC increased its holdings in shares of Aerovate Therapeutics by 310.8% in the 3rd quarter. Barclays PLC now owns 18,972 shares of the company’s stock valued at $39,000 after purchasing an additional 14,354 shares during the period. State Street Corp lifted its position in shares of Aerovate Therapeutics by 7.7% in the third quarter. State Street Corp now owns 367,468 shares of the company’s stock worth $768,000 after purchasing an additional 26,278 shares in the last quarter. FMR LLC boosted its holdings in shares of Aerovate Therapeutics by 54,095.4% during the third quarter. FMR LLC now owns 82,919 shares of the company’s stock worth $173,000 after purchasing an additional 82,766 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Aerovate Therapeutics during the second quarter valued at approximately $53,000.

Aerovate Therapeutics Trading Down 0.8 %

Aerovate Therapeutics stock opened at $2.57 on Wednesday. The firm’s 50 day moving average price is $2.59 and its two-hundred day moving average price is $2.27. Aerovate Therapeutics, Inc. has a twelve month low of $1.25 and a twelve month high of $32.42.

Aerovate Therapeutics (NASDAQ:AVTE) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.03. As a group, sell-side analysts expect that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.

Aerovate Therapeutics Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.